Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.PMID:38610638 | PMC:PMC11012464 | DOI:10.3390/jcm13071873

Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research